These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33564172)

  • 1. Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy.
    Himič V; Davies KE
    Eur J Hum Genet; 2021 Sep; 29(9):1369-1376. PubMed ID: 33564172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
    Aslesh T; Erkut E; Yokota T
    Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
    [No Abstract]   [Full Text] [Related]  

  • 4. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
    Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
    Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
    Wong TWY; Cohn RD
    Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duchenne muscular dystrophy: an updated review of common available therapies.
    Salmaninejad A; Valilou SF; Bayat H; Ebadi N; Daraei A; Yousefi M; Nesaei A; Mojarrad M
    Int J Neurosci; 2018 Sep; 128(9):854-864. PubMed ID: 29351004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy.
    Eslahi A; Alizadeh F; Avan A; Ferns GA; Moghbeli M; Reza Abbaszadegan M; Mojarrad M
    Gene; 2023 May; 867():147358. PubMed ID: 36914142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic therapeutic approaches for Duchenne muscular dystrophy.
    Foster H; Popplewell L; Dickson G
    Hum Gene Ther; 2012 Jul; 23(7):676-87. PubMed ID: 22647146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
    Choi E; Koo T
    Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
    Jarmin S; Kymalainen H; Popplewell L; Dickson G
    Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duchenne muscular dystrophy: genome editing gives new hope for treatment.
    Crispi V; Matsakas A
    Postgrad Med J; 2018 May; 94(1111):296-304. PubMed ID: 29386334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.
    Wilton SD; Fletcher S
    Curr Pharm Des; 2010; 16(8):988-1001. PubMed ID: 20041827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy.
    Goyenvalle A; Davies KE
    Methods Mol Biol; 2011; 709():179-96. PubMed ID: 21194028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CRISPR/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies.
    Agrawal P; Harish V; Mohd S; Singh SK; Tewari D; Tatiparthi R; Harshita ; Vishwas S; Sutrapu S; Dua K; Gulati M
    Life Sci; 2023 Oct; 330():122003. PubMed ID: 37544379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
    Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
    Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
    Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and Biochemical Assessment of Gene Therapy in the Canine Model of Duchenne Muscular Dystrophy.
    Hakim CH; Pérez-López D; Burke MJ; Teixeira J; Duan D
    Methods Mol Biol; 2023; 2587():255-301. PubMed ID: 36401035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene Therapy for Duchenne Muscular Dystrophy.
    Elangkovan N; Dickson G
    J Neuromuscul Dis; 2021; 8(s2):S303-S316. PubMed ID: 34511510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.